Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERGE: Upfront Radiosurgery for Residual Acromegaly
NCT03439709Phase 3Unknown
- Sponsor
- Samsung Medical Center
- Start
- Mar 2018
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Endocrinologic Remission at 2 years. Status: unknown.
Beyond the preview
Go deeper on NCT03439709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439709.